Treatment With OPN-305, a Humanized Anti–Toll-Like Receptor-2 Antibody, Reduces Myocardial Ischemia/Reperfusion Injury in Pigs | Zendy

Fatih Arslan | Zendy; Jaco H. Houtgraaf | Zendy; Brian Keogh | Zendy; Kushan Kazemi | Zendy; Renate de Jong | Zendy; William McCormack | Zendy; Luke O'neill | Zendy; Peter McGuirk | Zendy; Leo Timmers | Zendy; Mirjam B. Smeets | Zendy; Lars Akeroyd | Zendy; Mary M. Reilly | Zendy; Gerard Pasterkamp | Zendy; Dominique P.V. de Kleijn | Zendy

Open Access

Treatment With OPN-305, a Humanized Anti–Toll-Like Receptor-2 Antibody, Reduces Myocardial Ischemia/Reperfusion Injury in Pigs

Author(s) -

Fatih Arslan,

Jaco H. Houtgraaf,

Brian Keogh,

Kushan Kazemi,

Renate de Jong,

William McCormack,

Luke O'neill,

Peter McGuirk,

Leo Timmers,

Mirjam B. Smeets,

Lars Akeroyd,

Mary M. Reilly,

Gerard Pasterkamp,

Dominique P.V. de Kleijn

Publication year - 2012

Publication title -

circulation cardiovascular interventions

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.621

H-Index - 95

eISSN - 1941-7632

pISSN - 1941-7640

DOI - 10.1161/circinterventions.111.967596

Subject(s) - medicine , reperfusion injury , ischemia , cardiology , myocardial reperfusion injury , receptor , antibody , myocardial ischemia , toll like receptor , pharmacology , anesthesia , immunology , innate immune system

Toll-like receptor (TLR)-2 is an important mediator of innate immunity and ischemia/reperfusion-induced cardiac injury. We have previously shown that TLR2 inhibition reduces infarct size and improves cardiac function in mice. However, the therapeutic efficacy of a clinical grade humanized anti-TLR2 antibody, OPN-305, in a large-animal model remained to be addressed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research